JOINN Labs H1 Net Profit Surges 1,126.8% to RMB 748 Million
JOINN Laboratories reported a 1,126.8% year-on-year surge in first-half net profit to RMB 748 million, driven by strong contract signings in antibody, small nucleic acid, peptide, and nucleic acid drugs. Revenue rose 5.27% to RMB 704 million, with EPS at RMB 1.
JOINN Laboratories disclosed its semi-annual report on August 28, 2026. In the first half of 2026, the company achieved operating revenue of RMB 704 million, up 5.27% year-on-year. Net profit attributable to shareholders of the listed company reached RMB 748 million, a year-on-year increase of 1,126.8%. Basic earnings per share stood at RMB 1.
During the reporting period, the company saw a significant year-on-year surge in project signings for antibodies, small nucleic acids, peptides, and nucleic acid drugs. High-difficulty, long-cycle tests such as non-human primate reproductive toxicity and carcinogenicity studies also maintained a steady upward trend.